Loading...

Bionano Genomics, Inc.

BNGONASDAQ
HealthcareMedical - Diagnostics & Research
$3.91
$0.07(1.94%)

Bionano Genomics, Inc. (BNGO) Stock Overview

Explore Bionano Genomics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth
-14.79%
14.79%
Profit Growth
$-60.05
51.82%
EPS Growth
$-60.05
781.79%
Operating Margin
-324.90%
51.69%
ROE
-181.15%
51.82%
Dividend Yield
0.00%

Analyst Recommendations

Strong Buy
0
Buy
0
Hold
1
Sell
0
Strong Sell
0

Price Targets

Low$1.00
Average$1.50
High$2.00

Company Profile

Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.

CEO

Dr. Robert Erik Holmlin M.B.A., Ph.D.

Employees

98

Headquarters

9540 Towne Centre Drive, San Diego, CA

Founded

2018

Frequently Asked Questions

Meyka LogoMeyka

Meyka is the best Alternative Data platform powered by AI providing research insights for investors

Connect With Us

Legal Disclaimer

The information provided by Meyka AI PTY LTD is for informational and research purposes only and does not constitute financial, investment, or trading advice. Meyka is a research platform, not a financial advisory service. Investing in financial markets involves risks, and past performance does not guarantee future results. Users should conduct their own due diligence, consult with professional financial advisors, and assess their risk tolerance before making investment decisions. Meyka and its operators are not liable for any financial losses incurred from the use of information on this platform. The data provided is derived from publicly available sources and is believed to be reliable but may not always be accurate or up to date. Users should independently verify information and not rely solely on Meyka for financial decisions. By using Meyka, you acknowledge that it does not provide financial advice or recommendations and agree to seek guidance from a qualified financial professional before making any investment decisions.

© 2025 Meyka AI PTY LTD. All rights reserved.